Brokerages expect Inspire Medical Systems, Inc. (NYSE:INSP – Get Rating) to report ($0.61) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Inspire Medical Systems’ earnings. The lowest EPS estimate is ($0.71) and the highest is ($0.46). Inspire Medical Systems posted earnings of ($0.48) per share during the same quarter last year, which indicates a negative year over year growth rate of 27.1%. The firm is scheduled to report its next earnings report on Monday, January 1st.
On average, analysts expect that Inspire Medical Systems will report full-year earnings of ($2.11) per share for the current fiscal year, with EPS estimates ranging from ($2.49) to ($1.71). For the next year, analysts anticipate that the company will report earnings of ($1.51) per share, with EPS estimates ranging from ($2.20) to ($0.68). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Inspire Medical Systems.
Inspire Medical Systems (NYSE:INSP – Get Rating) last issued its earnings results on Tuesday, May 3rd. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.12. Inspire Medical Systems had a negative return on equity of 19.02% and a negative net margin of 16.20%. The firm had revenue of $69.40 million during the quarter, compared to analysts’ expectations of $64.17 million. During the same period last year, the business earned ($0.60) earnings per share. Inspire Medical Systems’s quarterly revenue was up 93.6% compared to the same quarter last year.
In other news, CFO Richard Buchholz sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, April 1st. The shares were sold at an average price of $258.67, for a total value of $3,880,050.00. Following the completion of the sale, the chief financial officer now directly owns 47,176 shares in the company, valued at approximately $12,203,015.92. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Timothy P. Herbert sold 20,000 shares of the stock in a transaction that occurred on Thursday, March 17th. The shares were sold at an average price of $225.40, for a total value of $4,508,000.00. The disclosure for this sale can be found here. Insiders have sold 52,143 shares of company stock valued at $12,848,826 in the last 90 days. 5.00% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Leverty Financial Group LLC bought a new position in Inspire Medical Systems during the 4th quarter valued at about $25,000. Assetmark Inc. purchased a new position in Inspire Medical Systems during the third quarter valued at $33,000. Rockefeller Capital Management L.P. increased its holdings in Inspire Medical Systems by 80.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 144 shares of the company’s stock worth $33,000 after acquiring an additional 64 shares in the last quarter. Covestor Ltd bought a new stake in shares of Inspire Medical Systems during the 4th quarter valued at $35,000. Finally, Parkside Financial Bank & Trust purchased a new position in shares of Inspire Medical Systems in the first quarter valued at about $37,000. Institutional investors and hedge funds own 93.98% of the company’s stock.
NYSE INSP opened at $175.90 on Friday. Inspire Medical Systems has a one year low of $142.74 and a one year high of $286.29. The firm has a market cap of $4.85 billion, a PE ratio of -112.76 and a beta of 1.65. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.08 and a quick ratio of 5.57. The stock’s 50 day simple moving average is $222.18 and its 200 day simple moving average is $228.87.
Inspire Medical Systems Company Profile (Get Rating)
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
- Get a free copy of the StockNews.com research report on Inspire Medical Systems (INSP)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.